Reimagining Medicine Q2 2023 Results

Company overview Innovation: Pipeline overview Financial review Financial performance Conclusions Appendix Innovation: Clinical trials References Abbreviations FINANCIAL PROFILE Net debt increased by USD 8.2bn mainly due to dividends and share buybacks, partly offset by FCF USD bn -7.2 -7.3 -5.7 Dec 31, 2022 Dividends Treasury share transactions, net 41 Investor Relations | Q2 2023 Results -8.2 -0.9 M&A/Intangible assets transactions, net -0.3 -15.4 6.0 Free Cash Flow Others June 30, 2023 NOVARTIS | Reimagining Medicine

View entire presentation